Clinical Trial: Local Therapy After FLAURA2 in EGFR-mutant NSCLC (PNU-0002)

U.S., July 19 -- ClinicalTrials.gov registry received information related to the study (NCT07073365) titled 'Local Therapy After FLAURA2 in EGFR-mutant NSCLC (PNU-0002)' on July 09.

Brief Summary: This is a single-arm, open-label, phase II study evaluating the clinical outcomes of local therapy (surgery or radiotherapy) to the primary tumor in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who have achieved disease control following first-line treatment with the FLAURA2 regimen (osimertinib plus platinum-based chemotherapy). The primary objective is to assess 1-year progression-free survival (PFS) after local therapy.

Study Start Date: July 01

Study Type: INTERVENTIONAL

Condition: Non-Small Cell Lung Cancer Epide...